What Is BriaCell Therapeutics Corp. (BCTX) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on BriaCell Therapeutics Corp. at its current price of $3.94. The composite intrinsic value is estimated at $3.27 (-16.9% average return), with 4 models flagging overvaluation risk. Model dispersion is worth noting: Sentiment SOTP targets $5.13 (+30.1%), versus ML-RIV at $0.38 (-90.4%). This +120.5% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About BCTX?
7 of 13 models are currently active for BCTX. Of these, 3 models suggest upside while 4 models suggest overvaluation. The Bayesian DCF estimates BCTX's intrinsic value at $1.16, implying -70.7% downside from the current price. See which stocks rank higher →
How Does BCTX Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, BCTX ranks #292 by Quality of Company score. CirclFi's QOC score of 4.4/10 evaluates 32 fundamental signals. A score of 4.4 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Within the Pharmaceutical Preparations space, BriaCell Therapeutics Corp. competes in an environment where pipeline depth and stage distribution often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is BCTX a Value Trap?
CirclFi's Value Trap algorithm assigns BCTX a score of 24/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
7 of 13 models are active for BriaCell Therapeutics Corp.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, BriaCell Therapeutics Corp. is rated at 4.4/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.
The gap between the most bullish and bearish model spans +120.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every BCTX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across BCTX's 7 active models, average confidence is 26%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad